Starting with keen biological and structural insights from the Springer lab, Morphic leverages that competitive advantage with cutting edge modeling technology and innovative drug design strategies to rapidly advance new innovative therapies.
Morphic established an exclusive integrin partnership with Schrödinger, the leader in chemical modeling and in silico drug discovery, which allows us to design, iterate, and optimize leads using a variety of next-generation physics-based technologies, augmented with machine learning and artificial intelligence, utilizing their massive computational clusters.
Since its founding, Morphic has built an integrin focused chemical library, which enables rapid discovery and advancement of new drug leads. This is coupled with deep platform knowledge of integrin inhibitors, including selectivity, physiochemical properties and PK, allowing quick discovery of clinical development candidates to treat human diseases.
Our partnership with Schrödinger LLC® enables us to design molecules with atomic precision utilizing state of art structure-guided drug design technology with the following key software technologies:
Unique Structure Determination Platform
- Capability to solve structures for all high priority targets
- Numerous proprietary structures over 9 different integrins
- Proprietary constructs, cell lines, and crystallization know-how
Schrödinger Computational Platform
Our partnership with Schrödinger LLC® enables us to design molecules with atomic precision utilizing state of the art structure-guided drug design technology with the following key software technologies: FEP+ for free energy calculation; Glide for ligand-receptor binding; Induced Fit for prediction of ligand induced conformational changes in receptor active sites; and WaterMap for ligand optimization – to name a few.
Integrin Inhibitor Design Platform
- Design of inhibitors for disease appropriate integrin state
- Assays to select the best inhibitors and to fully characterize them
- PK/PD analyses and optimization
- Translational biology capabilities